Rouen

• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended recruitment
  2022-502593-17-00 5 2023-09-19 Locally advanced or metastatic hormone receptor (HR)-positive, human e
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal t … Ended recruitment
  2024-511917-40-00 4 2022-09-13 Advanced Upper Gastrointestinal Tract Malignancies
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• A Study to Evaluate Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Len … Ended recruitment
  2023-505807-21-00 5 2021-11-16 Relapsed/refractory follicular lymphoma
• FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated … Ended recruitment
  2024-513936-80-00 4 2021-11-12 elderly patients (> 70 years) with CLL or SLL
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA … Ended recruitment
  2024-513252-15-00 4 2021-01-28 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
• Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended recruitment
  2023-503384-41-00 5 2020-12-22 Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
• Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk … Ended recruitment
  2023-507153-16-00 5 2020-11-18 Higher-Risk Myelodysplastic Syndrome
• Post-operative adjuvant treatment for HPV-positive tumours Ended recruitment
  2024-516673-68-00 5 2020-10-27 Human papillomavirus (HPV)-positive oropharyngeal cancer
• Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended recruitment
  2024-513005-31-00 5 2020-06-11 Patients with untreated metastatic Estrogen Receptor positive (ER+), H
• Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer Ended recruitment
  2023-503831-17-00 4 2019-12-23 The treatment of participants with HRRm and/or HRD-positive cancer
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, … Ended recruitment
  2024-516847-23-00 4 2019-08-27 ER-positive and HER2-negative metastatic or locally advanced breast ca
• Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different … Ended recruitment
  2024-514706-31-01 5 2019-05-02 Epithelial ovarian cancer, Fallopian tube ovarian cancer, Peritoneal o
• Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1 Ended recruitment
  2024-515352-20-00 4 2019-03-20 myelodysplastic syndrome with IDH1 mutated
• Phase III randomised trial evaluating chemotherapy early treatment intensification with temozolomide in adults present with a glioblastoma Ended recruitment
  2022-500451-23-00 5 2019-03-18 Adults with a de novo glioblastoma
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended recruitment
  2024-513206-65-00 5 2018-08-10 resected squamous cell carcinoma of head and neck
• Myechild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Fin … Ended recruitment
  2024-516112-21-00 5 2017-11-20 Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplast

Showing 121–144 of 173 trials